Pathogenesis of myeloproliferative neoplasms

Slides:



Advertisements
Similar presentations
MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.
Advertisements

NEOPLASTIC DISORDERS OF THE BONE MARROW
Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD.
APMG Pathologist, MD FCAP
MPD. Myeloproliferative neoplasms (MPN) constitute one of five categories of myeloid malignancies, according to the World Health Organization (WHO) classification.
Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010.
Myeloproliferative Disorders (MPD) concepts Neoplastic (clonal) disorders of hemopoietic stem cells Over-production of all cell lines, with usually one.
The Chronic Myeloproliferative Disorders (MPD) A JENABIAN MD.
Good morning… My presentation is about Calreticulin and PMF
Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
골수증식 질환 Myeloproliferative disorders (MPD) [ 새로운 분류와 진단 기준 ] 경희의대 종양혈액내과 조 경 삼.
Nada Mohamed Ahmed, MD, MT (ASCP)i. Objectives chronic myeloid leukaemia (CML) Haematopoietic malignancies Polycythemia vera (PV) Idiopathic myelofibrosis.
Fabian Mohr, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat 
Update of Molecular Genetics of Myeloproliferative Neoplasms
MYELOPROLIFERATIVE DISEASES
Myelodysplastic Syndromes
Volume 13, Issue 4, Pages (December 2006)
Diagnostic algorithm for suspected primary myelofibrosis
Diagnostic algorithm for suspected essential thrombocythemia
Experimental Hematology
Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology
Do you have any suggestions? Please contact us!
The JAK-STAT signal-transduction pathway
Transcriptional activation by MLL fusion proteins in leukemogenesis
Myeloproliferative Disoreders, Myelodysplastic, AML and Lymphomas: Recent Advances. Dr A S Akanmu Professor Of Haematology & Blood Transfusion. College.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Chronic Leukemia Kristine Krafts, M.D..
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Acute leukemia: A pediatric perspective
V617F “JAKs” up myeloproliferative signal
Cassie J. Clarke, Tessa L. Holyoake  Experimental Hematology 
by Mario Cazzola, Marianna Rossi, and Luca Malcovati
Myelodysplastic Syndromes
Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms  Jerald Z. Gong, James R. Cook, Timothy.
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies  Pankaj.
Ayalew Tefferi, MD, Tiziano Barbui, MD  Mayo Clinic Proceedings 
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia  Fabrice Usseglio, Nathalie Beaufils, Anne Calleja, Sophie.
Wanlong Ma, Hagop Kantarjian, Xi Zhang, Chen-Hsiung Yeh, Zhong J
Volume 13, Issue 4, Pages (December 2006)
Nat. Rev. Rheumatol. doi: /nrrheum
by R. Coleman Lindsley, and Benjamin L. Ebert
Velizar Shivarov, Lars Bullinger  Experimental Hematology 
Volume 13, Issue 4, Pages (December 2006)
Chronic Myeloid Leukemia
Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation 
Alison A. Laing, Christine J. Harrison, Brenda E. S
RASopathy Gene Mutations in Melanoma
A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Oceans of opportunity: Exploring vertebrate hematopoiesis in zebrafish
Induced pluripotent stem cell modeling of malignant hematopoiesis
Hematology Journal Club
Christopher E. Schmitt, Carlos O. Lizama, Ann C. Zovein 
Polycytemia Dr. Mamlook Elmagraby.
Ayalew Tefferi, Pierre Noel, Curtis A. Hanson 
Iléana Antony-Debré, Ulrich Steidl  Cancer Cell 
Peter Karagiannis, Shinya Yamanaka, Megumu K. Saito 
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms  Janine Prick, Gerald de Haan, Anthony R. Green,
Inside This Issue Experimental Hematology
Fabian Mohr, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat 
Pharmacological activation of wild-type p53 in the therapy of leukemia
Kinase signaling and targeted therapy for primary myelofibrosis
Ashley A. Newcombe, Brenda E.S. Gibson, Karen Keeshan 
Erratum Experimental Hematology
Sanger sequencing results
The Non – Leukemic Myeloproliferative Disorders
Presentation transcript:

Pathogenesis of myeloproliferative neoplasms Radek C. Skoda, Adrian Duek, Jean Grisouard  Experimental Hematology  Volume 43, Issue 8, Pages 599-608 (August 2015) DOI: 10.1016/j.exphem.2015.06.007 Copyright © 2015 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 1 Frequency and distribution of acquired gene mutations in hematologic malignancies. The red portions of the horizontal bars indicate the approximate frequencies of the mutations in the different disease entities. ALL = acute lymphocytic leukemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; CNL = chronic neutrophilic leukemia; ET = essential thrombocythemia; MDS = myelodysplastic syndromes; MPN = myeloproliferative neoplasms; PMF = primary myelofibrosis; PV = polycythemia vera; RARS-T = refractory anemia with ring sideroblasts and thrombocytosis; sAML = secondary acute myeloid leukemia. Experimental Hematology 2015 43, 599-608DOI: (10.1016/j.exphem.2015.06.007) Copyright © 2015 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 2 (A) Domain structure of the Jak2 protein. Numbers indicate amino acid positions within the Jak2 protein. Arrows indicate the positions of the most frequently mutated regions. The auto-inhibitory effect of the JH2 domain is indicated in yellow. FERM = N-terminal Band 4.1, ezrin, radixin, moesin domain; JH1 and JH2 = Jak homology 1 and 2 domains; SH2 = Src homology 2 domain. (B) Model of the interactions between the domains of the Jak2 protein bound to the erythropoietin receptor (EpoR). F = FERM domain; K = kinase domain (JH1); SH = SH2 domain. Experimental Hematology 2015 43, 599-608DOI: (10.1016/j.exphem.2015.06.007) Copyright © 2015 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 3 Model summarizing the known and hypothetical roles of Stat proteins in erythropoiesis and megakaryopoiesis in mice expressing JAK2-V617F. Arrows indicate stimulatory effects; T-Bars indicate inhibitory effects. Epo = erythropoietin; EpoR = erythropoietin receptor; Mpl = thrombopoietin receptor; Tpo = thrombopoietin. Experimental Hematology 2015 43, 599-608DOI: (10.1016/j.exphem.2015.06.007) Copyright © 2015 ISEH - International Society for Experimental Hematology Terms and Conditions